Specialty medications, which can cost between $10,000 and upward of $5 million, now account for 52% of U.S. pharmaceutical sales, according to a Dec. 30 report from the Healthcare Distribution ...

2025 might shape out to be a boon year for pharma, a recent report from Norstella’s Evaluate suggests. The 2025 Preview Report examines the “biggest movers and shakers” in the biotech and pharma ...

With sluggish pharmaceutical sales in the third quarter coming in below analysts’ expectations, Bayer is acutely aware of the challenges facing its key unit. Nevertheless, at least as far as ...

Please provide your email address to receive an email when new articles are posted on . Boy, I know that there are some really terrible jobs in the extended health care universe, but it sure seems ...

LONDON--(BUSINESS WIRE)--As coronavirus continues to wreak havoc across industries, Quantzig’s sales analytics experts analyze the recent challenges in the pharmaceutical industry and explain why a ...

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) in Q1 CY2025, with sales up 14.8% year on year to $745.1 million. The company expects the full year’s revenue to be around $3.15 billion, close to ...

CEO Eric Green highlighted that the company achieved 3.3% organic revenue growth in Q4 2024, marking a return to quarterly growth. Notable drivers included strong performance in Biologics and the ...

While 2025 was the year of disruption for Trump’s pharma policies, we expect 2026 to be the year of truth: will the US ...

WASHINGTON - Attorneys general nationwide announced their approval Monday of a $7.4 billion settlement with pharmaceutical manufacturer Purdue Pharma over what they say was the company’s inappropriate ...

ARS Pharmaceuticals specializes in developing and commercializing treatments for severe allergic reactions. Its flagship product, neffy, is a needle-free epinephrine nasal spray approved for emergency ...